Abbott India Share Price
Sector: Biotechnology & Drugs
30650.00 +89.15 (0.29%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
30535.05
Today’s High
30890.00
52 Week Low
25260.20
52 Week High
31900.00
30685.00 +125.00 (0.41%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
30555.00
Today’s High
30860.00
52 Week Low
25325.00
52 Week High
31898.95
Key Metrics
- Market Cap (In Cr) 65325.27
- Beta -0.03
- Div. Yield (%) 1.55
- P/B 15.34
- TTM P/E 46.15
- Peg Ratio 2.19
- Sector P/E 24.5
- D/E 0
- Open Price 30570.55
- Prev Close 30560.85
Abbott India Analysis
Price Analysis
-
1 Week1.31%
-
3 Months9.77%
-
6 Month11.73%
-
YTD2.75%
-
1 Year15.14%
Risk Meter
- 25% Low risk
- 25% Moderate risk
- 25% Balanced Risk
- 25% High risk
- 25% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 2
- Buy
- 2
- 2
- 2
- 2
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 5
- 5
- 5
- 4
Abbott India News
Stocks to watch: Bharti Airtel, Hyundai Motor, BHEL among shares in focus today
1 min read . 16 May 2025Q4 results today: ITC Hotels, Cochin Shipyard, JSW Energy and more on May 15
1 min read . 15 May 2025Four Australian players in PSL narrowly avoid missile strikes: Australian media
1 min read . 10 May 2025Recommended stocks to watch: Top 8 stock picks by market experts for 25 February
2 min read . 25 Feb 2025Abbott India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 6409.15
- Selling/ General/ Admin Expenses Total
- 587.54
- Depreciation/ Amortization
- 71.8
- Other Operating Expenses Total
- 630.23
- Total Operating Expense
- 4786.35
- Operating Income
- 1622.8
- Net Income Before Taxes
- 1886.95
- Net Income
- 1414.44
- Diluted Normalized EPS
- 665.62
- Period
- 2025
- Total Assets
- 5917.31
- Total Liabilities
- 1684.16
- Total Equity
- 4233.15
- Tangible Book Valueper Share Common Eq
- 1989.1
- Period
- 2025
- Cashfrom Operating Activities
- 1011.84
- Cashfrom Investing Activities
- 182.18
- Cashfrom Financing Activities
- -925.17
- Net Changein Cash
- 268.85
- Period
- 2024
- Total Revenue
- 5848.91
- Selling/ General/ Admin Expenses Total
- 1118.08
- Depreciation/ Amortization
- 71.17
- Other Operating Expenses Total
- 25.07
- Total Operating Expense
- 4463.28
- Operating Income
- 1385.63
- Net Income Before Taxes
- 1617.75
- Net Income
- 1201.22
- Diluted Normalized EPS
- 565.24
- Period
- 2024
- Total Assets
- 5193.49
- Total Liabilities
- 1494.6
- Total Equity
- 3698.89
- Tangible Book Valueper Share Common Eq
- 1737.58
- Period
- 2024
- Cashfrom Operating Activities
- 1212.81
- Cashfrom Investing Activities
- -416.03
- Cashfrom Financing Activities
- -744.71
- Net Changein Cash
- 52.07
- Period
- 2023
- Total Revenue
- 5348.73
- Selling/ General/ Admin Expenses Total
- 1069.93
- Depreciation/ Amortization
- 69.97
- Other Operating Expenses Total
- 66.33
- Total Operating Expense
- 4206.75
- Operating Income
- 1141.98
- Net Income Before Taxes
- 1273.82
- Net Income
- 949.41
- Diluted Normalized EPS
- 446.68
- Period
- 2023
- Total Assets
- 4555.51
- Total Liabilities
- 1366.97
- Total Equity
- 3188.54
- Tangible Book Valueper Share Common Eq
- 1497
- Period
- 2023
- Cashfrom Operating Activities
- 893.39
- Cashfrom Investing Activities
- -147.71
- Cashfrom Financing Activities
- -638.72
- Net Changein Cash
- 106.96
- Period
- 2022
- Total Revenue
- 4919.27
- Selling/ General/ Admin Expenses Total
- 1086.89
- Depreciation/ Amortization
- 66.1
- Other Operating Expenses Total
- 57.26
- Total Operating Expense
- 3892.34
- Operating Income
- 1026.93
- Net Income Before Taxes
- 1079.73
- Net Income
- 798.7
- Diluted Normalized EPS
- 375.87
- Period
- 2022
- Total Assets
- 4224.12
- Total Liabilities
- 1404.33
- Total Equity
- 2819.79
- Tangible Book Valueper Share Common Eq
- 1322.94
- Period
- 2022
- Cashfrom Operating Activities
- 947.66
- Cashfrom Investing Activities
- -395.84
- Cashfrom Financing Activities
- -637.38
- Net Changein Cash
- -85.56
- Period
- 2021
- Total Revenue
- 4310.02
- Selling/ General/ Admin Expenses Total
- 918.82
- Depreciation/ Amortization
- 58.13
- Other Operating Expenses Total
- 53.77
- Total Operating Expense
- 3441.5
- Operating Income
- 868.52
- Net Income Before Taxes
- 925.95
- Net Income
- 690.69
- Diluted Normalized EPS
- 325.12
- Period
- 2021
- Total Assets
- 3840.45
- Total Liabilities
- 1238.29
- Total Equity
- 2602.16
- Tangible Book Valueper Share Common Eq
- 1224.04
- Period
- 2021
- Cashfrom Operating Activities
- 726.74
- Cashfrom Investing Activities
- -71.82
- Cashfrom Financing Activities
- -581.79
- Net Changein Cash
- 73.13
- Period
- 2020
- Total Revenue
- 4093.14
- Selling/ General/ Admin Expenses Total
- 929.42
- Depreciation/ Amortization
- 59.61
- Other Operating Expenses Total
- 59.3
- Total Operating Expense
- 3386.48
- Operating Income
- 706.66
- Net Income Before Taxes
- 802.69
- Net Income
- 592.93
- Diluted Normalized EPS
- 279.22
- Period
- 2020
- Total Assets
- 3546.85
- Total Liabilities
- 1115.14
- Total Equity
- 2431.71
- Tangible Book Valueper Share Common Eq
- 1143.95
- Period
- 2020
- Cashfrom Operating Activities
- 626.11
- Cashfrom Investing Activities
- -401.19
- Cashfrom Financing Activities
- -216.79
- Net Changein Cash
- 8.13
- Period
- 2019
- Total Revenue
- 3678.6
- Selling/ General/ Admin Expenses Total
- 914.55
- Depreciation/ Amortization
- 16.92
- Other Operating Expenses Total
- 47
- Total Operating Expense
- 3085.21
- Operating Income
- 593.4
- Net Income Before Taxes
- 698.85
- Net Income
- 450.33
- Diluted Normalized EPS
- 209
- Period
- 2019
- Total Assets
- 2940.91
- Total Liabilities
- 932.33
- Total Equity
- 2008.59
- Tangible Book Valueper Share Common Eq
- 944.38
- Period
- 2019
- Cashfrom Operating Activities
- 499.13
- Cashfrom Investing Activities
- -257
- Cashfrom Financing Activities
- -142.8
- Net Changein Cash
- 99.33
- Period
- 2025-03-31
- Total Revenue
- 1604.59
- Selling/ General/ Admin Expenses Total
- 144.4
- Depreciation/ Amortization
- 17.93
- Other Operating Expenses Total
- 175.69
- Total Operating Expense
- 1193.98
- Operating Income
- 410.61
- Net Income Before Taxes
- 482.71
- Net Income
- 367.04
- Diluted Normalized EPS
- 172.72
- Period
- 2025-03-31
- Total Assets
- 5917.31
- Total Liabilities
- 1684.16
- Total Equity
- 4233.15
- Tangible Book Valueper Share Common Eq
- 1989.1
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 1011.84
- Cashfrom Investing Activities
- 182.18
- Cashfrom Financing Activities
- -925.17
- Net Changein Cash
- 268.85
- Period
- 2024-12-31
- Total Revenue
- 1614.28
- Selling/ General/ Admin Expenses Total
- 134.68
- Depreciation/ Amortization
- 17.99
- Other Operating Expenses Total
- 150.81
- Total Operating Expense
- 1196.18
- Operating Income
- 418.1
- Net Income Before Taxes
- 487.59
- Net Income
- 360.78
- Diluted Normalized EPS
- 169.78
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1632.67
- Selling/ General/ Admin Expenses Total
- 147.4
- Depreciation/ Amortization
- 17.51
- Other Operating Expenses Total
- 144.55
- Total Operating Expense
- 1211.22
- Operating Income
- 421.45
- Net Income Before Taxes
- 479.43
- Net Income
- 358.61
- Diluted Normalized EPS
- 168.76
- Period
- 2024-09-30
- Total Assets
- 5063.02
- Total Liabilities
- 1541.91
- Total Equity
- 3521.11
- Tangible Book Valueper Share Common Eq
- 1653.31
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 481.95
- Cashfrom Investing Activities
- 762.53
- Cashfrom Financing Activities
- -898.53
- Net Changein Cash
- 345.95
- Period
- 2024-06-30
- Total Revenue
- 1557.61
- Selling/ General/ Admin Expenses Total
- 161.06
- Depreciation/ Amortization
- 18.37
- Other Operating Expenses Total
- 159.18
- Total Operating Expense
- 1184.97
- Operating Income
- 372.64
- Net Income Before Taxes
- 437.22
- Net Income
- 328.01
- Diluted Normalized EPS
- 154.36
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1438.63
- Selling/ General/ Admin Expenses Total
- 145.24
- Depreciation/ Amortization
- 18.19
- Other Operating Expenses Total
- 157.96
- Total Operating Expense
- 1127.29
- Operating Income
- 311.34
- Net Income Before Taxes
- 389.68
- Net Income
- 287.06
- Diluted Normalized EPS
- 135.11
- Period
- 2024-03-31
- Total Assets
- 5193.49
- Total Liabilities
- 1494.6
- Total Equity
- 3698.89
- Tangible Book Valueper Share Common Eq
- 1737.58
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1212.81
- Cashfrom Investing Activities
- -416.03
- Cashfrom Financing Activities
- -744.71
- Net Changein Cash
- 52.07
- Period
- 2023-12-31
- Total Revenue
- 1437.14
- Selling/ General/ Admin Expenses Total
- 139.19
- Depreciation/ Amortization
- 17.97
- Other Operating Expenses Total
- 133.47
- Total Operating Expense
- 1067.42
- Operating Income
- 369.72
- Net Income Before Taxes
- 422.16
- Net Income
- 310.98
- Diluted Normalized EPS
- 146.34
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Abbott India Technical
Moving Average
SMA
- 5 Day30349.49
- 10 Day30309.77
- 20 Day30317.59
- 50 Day30310.55
- 100 Day29397.39
- 300 Day28964.92
Abbott India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Lupin
- 2028.8
- -39.55
- -1.91
- 2403.45
- 1493.75
- 92788.65
- Zydus Lifesciences
- 911.4
- 8.4
- 0.93
- 1323.9
- 797.05
- 91556.08
- Abbott India
- 30650
- 89.15
- 0.29
- 31900
- 25260.2
- 65325.27
- Alkem Laboratories
- 5328.05
- 107.05
- 2.05
- 6440
- 4409.9
- 63704.83
- Glaxosmithkline Pharmaceutical
- 2805.75
- -21.85
- -0.77
- 3147.45
- 1924.3
- 47640.33
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Lupin
- 28.85
- 5.49
- 7.86
- 5.95
- Zydus Lifesciences
- 23.81
- 4.58
- 15.65
- 14.33
- Abbott India
- 45.91
- 15.34
- 32.31
- 18.83
- Alkem Laboratories
- 34.71
- 6.05
- 18.26
- 13.94
- Glaxosmithkline Pharmaceutical
- 51.85
- 24.56
- 29.26
- 16.77
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 15-May-25
- Audited Results & Final Dividend
- 05-Feb-25
- Quarterly Results
- 07-Nov-24
- Quarterly Results
- 07-Aug-24
- Quarterly Results
- 09-May-24
- Audited Results & Final Dividend
- 01-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 13-Aug-25
- 15-May-25
- AGM
- 08-Aug-24
- 09-May-24
- AGM
- 09-Aug-23
- 19-May-23
- AGM
- 10-Aug-22
- 17-May-22
- AGM
- 28-Mar-22
- 23-Feb-22
- POM
- 27-Jul-21
- 18-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 15-May-25
- 25-Jul-25
- -
- 475
- 09-May-24
- 19-Jul-24
- 19-Jul-24
- 410
- 19-May-23
- 21-Jul-23
- 21-Jul-23
- 180
- 20-May-23
- 21-Jul-23
- 21-Jul-23
- 145
- 17-May-22
- -
- 02-Aug-22
- 145
- 18-May-22
- -
- 02-Aug-22
- 130
- 18-May-21
- -
- 19-Jul-21
- 120
- 19-May-21
- -
- 19-Jul-21
- 155


